← Ranking

RKLB · Rocket Lab Corp

Changes to watch · 17 concrete new risks (litigation, regulation, corporate transactions)

10-Q 2026-08-10 ↗ compared with the reference 10-K 10-K 2026-02-26 ↗

Closing price50-day average200-day average

Technical events and factor profile →

Summary

Rocket Lab warns of potential delays and costs from government conditions on its Iridium Transaction, including regulatory approvals in several countries. The company also faces increased litigation risks due to merger agreements. It will issue a large number of shares to finance the deal.

Automatic summary generated from the filing; it may contain inaccuracies.
Concrete new risks
17
Generic new risks
0
Filing
10-Q · 2026-08-10

How the stock reacted

After the 10-Q1 session5 sessions20 sessions
RKLB-3.4%-3.1%-22.4%
Nasdaq-100 (QQQ)-0.3%+1.1%-0.6%
Difference-3.1%-4.2%-21.9%

From the close before the filing. Historical data, not a prediction.

What the concrete new risks are about

Litigation · 5Regulation · 5Corporate transactions · 4Debt and liquidity · 3

New risks 17

Concrete fact Litigation
Government Conditions May Delay or Increase Costs

Governmental authorities may also impose conditions, terms, obligations or restrictions in connection with their approval of or consent to the Iridium Transaction, and such conditions, terms, obligations or restrictions may delay completion of the Iridium Transaction or impose additional material costs on, or materially limit the revenues of, Rocket Lab following the completion of the Iridium Transaction. There can be no assurance that governmental authorities will not impose any such conditions, terms, obligations or restrictions, and, if imposed, such conditions, terms, obligations or restrictions may delay or lead to the abandonment of the Iridium Transaction. At any time before or after consummation of the Iridium Transaction, notwithstanding any termination or expiration of the applicable waiting period under the HSR Act, the Federal Trade Commission, the U.S. Department of Justice or any state attorney general could take such action under the U.S. antitrust laws as it deems necessary or desirable in the public interest, including seeking (i) to enjoin the completion of the Iridium Transaction, (ii) to require the divestiture of substantial assets of or Iridium or our or their respective subsidiaries, (iii) to require the parties to license rights, hold separate assets, terminate existing relationships and contractual rights, grant certain rights or commercial accommodations to third parties, or agree to other restrictions limiting the freedom of action of the parties and their respective affiliates, or (iv) to require any other changes or restructuring of the parties and their respective affiliates. Private parties also may bring legal actions under the U.S. antitrust laws under certain circumstances, notwithstanding any termination or expiration of the applicable waiting periods under the HSR Act, seeking similar relief or seeking conditions to the completion of the Iridium Transaction. Neither we nor Iridium can be certain that a challenge to the Iridium Transaction on antitrust grounds will not be made or, if such a challenge is made, what the result will be. We will not be obligated to complete the Iridium Transaction if a non-appealable order prohibiting the Iridium Transaction is in effect, or if the Iridium Transaction has not been completed by the end date (as it may be extended).

16 more new risks

With Pro you see every new risk in each filing, with concrete facts separated from generic wording, and the filing history.

Go Pro

Already Pro? Log in

Key figures quarterly · USD

Revenue (TTM)
$769M
YoY growth
+62.0%
Operating margin
-24.6%
Cash / debt
$2.1B / $2M
Jun 26Mar 26Dec 25Sep 25Jun 25
Revenue$234M$200M$180M$155M$144M
YoY growth+62.0%+63.5%+35.7%+48.0%+36.0%
Gross margin36.1%38.2%38.0%37.0%32.1%
Operating margin-24.6%-27.9%-28.4%-38.0%-41.3%
Net income-$49M-$45M-$53M-$18M-$66M
Diluted EPS-0.08-0.07-0.09-0.03-0.13

XBRL data filed with the SEC. The fourth fiscal quarter is calculated as the full year minus the previous three quarters.

Factor profile percentile vs. the S&P 500 and the Nasdaq-100

Momentum
12 months excl. last: -2.1% · 6 months -40.0%
34
Trend quality
R² 0.51 · falling
12
Relative strength
-50.2% vs. the S&P 500 over 6 months
2
Volatility
68% annualised
94
Beta
beta 3.85
99
Distance from high
-66.2% from the 52-week high
0
Extension
-2.7 standard deviations from its 20-day average
2

0 = the lowest in the universe, 100 = the highest. It describes how the stock has behaved, not whether to buy or sell it. Screen stocks by factors

Management tone MD&A

+15

Similar than in the previous 10-Q (2026-05-07: +17, -2 points)

10-Q of 2026-08-10 · 29.6% positive sentences, 12.7% negative · 189 sentences analysed

Index from −100 to +100 calculated with FinBERT on the results discussion (MD&A). The change matters more than the level: some sectors always sound more cautious.

Top funds 13F

ARK Investment Management · Cathie Wood
held since Q2 2025
1.1% $165.8M -27%
Bridgewater Associates · Ray Dalio
held since Q3 2025
0.0% $1.1M -33%

Weight in each fund's portfolio and change vs. the previous quarter, from its latest 13F.

Recent material events (8-K)

2026-10-14 Investor communication (Reg FD)Other events SEC ↗
2026-09-15 Investor communication (Reg FD)Other events 5 sessions: +7.1% vs Nasdaq-100 SEC ↗
2026-08-13 Investor communication (Reg FD)Other events 5 sessions: -5.5% vs Nasdaq-100 SEC ↗
2026-08-13 Other events 5 sessions: -5.5% vs Nasdaq-100 SEC ↗
2026-08-10 Results released 5 sessions: +1.3% vs Nasdaq-100 SEC ↗
2026-06-29 Material agreement signedInvestor communication (Reg FD) 5 sessions: +7.8% vs Nasdaq-100 SEC ↗
2026-06-05 Executive or board changes 5 sessions: -9.3% vs Nasdaq-100 SEC ↗

All material events for RKLB →

Insiders · last 90 days

Buys
—
Discretionary sells
—
10b5-1 plan sells
$9.9M
2026-10-01 Spice Adam C. · CFO Sell (10b5-1 plan) $6.0M SEC ↗
2026-10-01 Spice Adam C. · CFO Sell (10b5-1 plan) $2.8M SEC ↗
2026-10-01 Spice Adam C. · CFO Sell (10b5-1 plan) $1.1M SEC ↗

Source: SEC EDGAR. Automatic comparison of the risk factors section; it may contain extraction errors. Always check the original document. For information purposes only; not investment advice.